Cambridge, MA – June 1 2023
XtalPi Inc., a pioneering AI-powered pharmaceutical technology company, has announced a strategic collaboration with Eli Lilly and Company (NYSE: LLY) to accelerate the discovery of first-in-class therapeutics. The collaboration, valued at up to $250 million in upfront and milestone payments, will leverage XtalPi’s AI-integrated robotics platform to design and develop novel drug candidates for an undisclosed target.
Transforming Drug Discovery with AI and Robotics
The partnership between XtalPi and Lilly signifies a major step toward a more efficient, AI-driven pharmaceutical R&D model. By combining XtalPi’s computational algorithms with large-scale autonomous lab robotics, this collaboration aims to revolutionize the drug discovery process, reducing both time and cost while enhancing precision.
“XtalPi is committed to redefining drug discovery through the synergy of AI, quantum physics, and automation,” said Dr. Jian Ma, CEO of XtalPi. “With a closed-loop system integrating AI-driven predictions and real-world experimental validation, we are honored to collaborate with Lilly to unlock new therapeutic possibilities.”
AI-Powered Precision in Small Molecule Drug Discovery
XtalPi’s proprietary ID4Inno™ platform integrates AI models, quantum mechanics simulations, and high-throughput robotic automation to identify novel chemical entities with high therapeutic potential. The platform generates extensive chemical libraries, optimizing candidates through iterative design-make-test-analyze (DMTA) cycles. Lilly will leverage these capabilities to pursue the clinical and commercial development of a novel compound resulting from this collaboration.
Scaling AI + Automation in Biopharma R&D
This partnership aligns with the growing industry shift toward AI-driven drug development. XtalPi’s autonomous robotic workstations operate 24/7, executing precise chemical synthesis and assays, generating high-quality real-world data, and continuously refining predictive AI models. By integrating computational and experimental capabilities, XtalPi enables a paradigm shift from labor-intensive trial-and-error research to a scalable, automation-driven model.
About XtalPi
XtalPi is a leading AI-driven pharmaceutical technology company that leverages AI, quantum mechanics, and robotic automation to accelerate drug discovery and development. With a global presence and collaborations with over 200 pharmaceutical and biotech companies, XtalPi is advancing the next generation of therapeutics.
More about news
By
